{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Effect+of+Drug&page=25",
    "query": {
      "condition": "Effect of Drug",
      "page": 25
    },
    "page_size": 10
  },
  "pagination": {
    "page": 25,
    "page_size": 10,
    "total_count": 1898,
    "total_pages": 190,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Effect+of+Drug&page=26&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Effect+of+Drug&page=24&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T14:38:21.582Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01779453",
      "title": "A Study of the Safety, Pharmacokinetic Drug Interaction and Efficacy of ETC-1002 and Atorvastatin in Subjects With Hypercholesterolemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hypercholesterolemia"
      ],
      "interventions": [
        {
          "name": "ETC-1002",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Atorvastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Esperion Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 58,
      "start_date": "2012-12",
      "completion_date": "2013-08",
      "has_results": false,
      "last_update_posted_date": "2019-03-29",
      "last_synced_at": "2026-11-15T14:38:21.582Z",
      "location_count": 3,
      "location_summary": "Indianapolis, Indiana • Louisville, Kentucky • Richmond, Virginia",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01779453"
    },
    {
      "nct_id": "NCT03140280",
      "title": "Hypomethylating Properties of Freeze-dried Black Raspberries (BRB) in Patients With Myelodysplastic Syndrome or Myelodysplastic Syndrome/Myeloproliferative Neoplasm (MDS/MPN)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Myelodysplastic Syndromes"
      ],
      "interventions": [
        {
          "name": "Freeze-Dried Black Raspberry Powder",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ehab L Atallah",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 23,
      "start_date": "2017-06-05",
      "completion_date": "2021-05-28",
      "has_results": true,
      "last_update_posted_date": "2022-11-04",
      "last_synced_at": "2026-11-15T14:38:21.582Z",
      "location_count": 1,
      "location_summary": "Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03140280"
    },
    {
      "nct_id": "NCT00983242",
      "title": "Drug-Drug Interaction Between Colchicine and Verapamil ER",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pharmacokinetics"
      ],
      "interventions": [
        {
          "name": "Colchicine",
          "type": "DRUG"
        },
        {
          "name": "Verapamil HCl ER",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mutual Pharmaceutical Company, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 24,
      "start_date": "2008-09",
      "completion_date": "2008-10",
      "has_results": true,
      "last_update_posted_date": "2009-10-15",
      "last_synced_at": "2026-11-15T14:38:21.582Z",
      "location_count": 1,
      "location_summary": "East Grand Forks, Minnesota",
      "locations": [
        {
          "city": "East Grand Forks",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00983242"
    },
    {
      "nct_id": "NCT06698926",
      "title": "A Study to Assess the Safety, Tolerability, and Interactions of ABBV-CLS-616 Oral Tablets in Healthy Adult Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteer"
      ],
      "interventions": [
        {
          "name": "ABBV-CLS-616",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Itraconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 110,
      "start_date": "2024-11-11",
      "completion_date": "2026-01-09",
      "has_results": false,
      "last_update_posted_date": "2026-01-15",
      "last_synced_at": "2026-11-15T14:38:21.582Z",
      "location_count": 1,
      "location_summary": "Grayslake, Illinois",
      "locations": [
        {
          "city": "Grayslake",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06698926"
    },
    {
      "nct_id": "NCT00983216",
      "title": "Drug-Drug Interaction Study Between Colchicine and Ketoconazole",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Pharmacokinetics"
      ],
      "interventions": [
        {
          "name": "Colchicine",
          "type": "DRUG"
        },
        {
          "name": "Ketoconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mutual Pharmaceutical Company, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "ALL",
        "summary": "18 Years to 45 Years"
      },
      "enrollment_count": 24,
      "start_date": "2008-07",
      "completion_date": "2008-08",
      "has_results": true,
      "last_update_posted_date": "2009-10-15",
      "last_synced_at": "2026-11-15T14:38:21.582Z",
      "location_count": 1,
      "location_summary": "Fargo, North Dakota",
      "locations": [
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00983216"
    },
    {
      "nct_id": "NCT02520752",
      "title": "A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "cMET-dysregulated Advanced Solid Tumors"
      ],
      "interventions": [
        {
          "name": "INC280",
          "type": "DRUG"
        },
        {
          "name": "Midazolam",
          "type": "DRUG"
        },
        {
          "name": "Caffeine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2015-12-10",
      "completion_date": "2017-09-12",
      "has_results": false,
      "last_update_posted_date": "2020-12-10",
      "last_synced_at": "2026-11-15T14:38:21.582Z",
      "location_count": 2,
      "location_summary": "Atlanta, Georgia • St Louis, Missouri",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02520752"
    },
    {
      "nct_id": "NCT04378881",
      "title": "Simulation of Risk of Adverse Drug Events Associated With the Initiation of Drugs Repurposed for the Treatment of COVID-19 in Adults With Polypharmacy Using Data From Large Medicare and Commercially Insured Populations",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "COVID",
        "Drug Effect",
        "Drug Interaction",
        "Adverse Drug Event"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Tabula Rasa HealthCare",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2020-06-12",
      "completion_date": "2023-11-11",
      "has_results": false,
      "last_update_posted_date": "2022-09-02",
      "last_synced_at": "2026-11-15T14:38:21.582Z",
      "location_count": 1,
      "location_summary": "Orlando, Florida",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04378881"
    },
    {
      "nct_id": "NCT00399698",
      "title": "Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Oppositional Defiant Disorder",
        "Conduct Disorder",
        "Attention Deficit/Hyperactivity Disorder (ADHD)",
        "Intermittent Explosive Disorder",
        "Impulse-Control Disorders",
        "Adjustment Disorder",
        "Bipolar Disorder",
        "Pervasive Developmental Disorder"
      ],
      "interventions": [
        {
          "name": "Risperdal",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ohio State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "4 Years",
        "maximum_age": "14 Years",
        "sex": "ALL",
        "summary": "4 Years to 14 Years"
      },
      "enrollment_count": 30,
      "start_date": "1999-05",
      "completion_date": "2005-06",
      "has_results": false,
      "last_update_posted_date": "2016-06-23",
      "last_synced_at": "2026-11-15T14:38:21.582Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00399698"
    },
    {
      "nct_id": "NCT01419899",
      "title": "Increasing Viral Testing in the Emergency Department",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Drug Use",
        "HIV",
        "Hepatitis C"
      ],
      "interventions": [
        {
          "name": "Brief motivational intervention",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Rhode Island Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 398,
      "start_date": "2011-01",
      "completion_date": "2012-01",
      "has_results": false,
      "last_update_posted_date": "2013-08-07",
      "last_synced_at": "2026-11-15T14:38:21.582Z",
      "location_count": 1,
      "location_summary": "Providence, Rhode Island",
      "locations": [
        {
          "city": "Providence",
          "state": "Rhode Island"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01419899"
    },
    {
      "nct_id": "NCT05266612",
      "title": "Phase I Study VG2025 as a Single Agent and in Combination Therapy With Nivolumab in Subjects With Advanced Malignant Solid Tumors",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Tumor"
      ],
      "interventions": [
        {
          "name": "VG2025",
          "type": "DRUG"
        },
        {
          "name": "Nivolumab Injection [Opdivo]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Virogin Biotech Canada Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2022-11-09",
      "completion_date": "2025-12-31",
      "has_results": false,
      "last_update_posted_date": "2024-08-09",
      "last_synced_at": "2026-11-15T14:38:21.582Z",
      "location_count": 2,
      "location_summary": "Gilbert, Arizona • Houston, Texas",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05266612"
    }
  ]
}